SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-013331 to EBR Systems, Inc. (EBRCZ) (CIK 0001347123) (EBRCZ)

EBR Systems, Inc. (EBRCZ) (CIK 0001347123)
Date: Dec. 3, 2024 · CIK: 0001347123 · Accession: 0000000000-24-013331

AI Filing Summary & Sentiment

File numbers found in text: 000-56671

Date
December 3, 2024
Author
Not clearly detected
Form
UPLOAD
Company
EBR Systems, Inc. (EBRCZ) (CIK 0001347123)

Letter

December 3, 2024 John McCutcheon Chief Executive Officer EBR Systems, Inc. 480 Oakmead Parkway Sunnyvale, CA 94085 Re:EBR Systems, Inc. Amendment No. 3 to Registration Statement on Form 10-12G Filed November 21, 2024 File No. 000-56671 Dear John McCutcheon: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-12G/A No. 3 filed November 21, 2024 Interim Financial Statements Pre-launch inventory, page F-37 1.We note that during the three months ended September 30, 2024 you have begun to capitalize certain pre-launch inventory. Please expand your disclosure herein, or within your Critical Accounting Estimates on page 75, to provide the following additional disclosures: •Specifically identify the point during the FDA approval process that you determined a probable future benefit existed and the status of the FDA’s consideration of the safety and efficacy of the system and evaluation of the manufacturing process at that point. •Identify the risks and uncertainties surrounding market acceptance of the system once approved and how this will affect the realization of the asset.

December 3, 2024 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tayyaba Shafique at 202-551-2110 or Jeanne Baker at 202-551-3691 if you have questions regarding comments on the financial statements and related matters. Please contact Nicholas O'Leary at 202-551-4451 or Lauren Nguyen at 202-551- 3642 with any other questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:John Sellers, Esq.

Show Raw Text
December 3, 2024
John McCutcheon
Chief Executive Officer
EBR Systems, Inc.
480 Oakmead Parkway
Sunnyvale, CA 94085
Re:EBR Systems, Inc.
Amendment No. 3 to Registration Statement on Form 10-12G
Filed November 21, 2024
File No. 000-56671
Dear John McCutcheon:
            We have reviewed your filing and have the following comment.
            Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
            After reviewing your response to this letter, we may have additional comments.
Form 10-12G/A No. 3 filed November 21, 2024
Interim Financial Statements
Pre-launch inventory, page F-37
1.We note that during the three months ended September 30, 2024 you have begun to
capitalize certain pre-launch inventory.  Please expand your disclosure herein, or
within your Critical Accounting Estimates on page 75, to provide the following
additional disclosures:
•Specifically identify the point during the FDA approval process that you
determined a probable future benefit existed and the status of the FDA’s
consideration of the safety and efficacy of the system and evaluation of the
manufacturing process at that point.
•Identify the risks and uncertainties surrounding market acceptance of the
system once approved and how this will affect the realization of the asset.

December 3, 2024
Page 2
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence
of action by the staff.
            Please contact Tayyaba Shafique at 202-551-2110 or Jeanne Baker at 202-551-3691 if
you have questions regarding comments on the financial statements and related
matters. Please contact Nicholas O'Leary at 202-551-4451 or Lauren Nguyen at 202-551-
3642 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:John Sellers, Esq.